Identification of cognitively impaired patients at risk for development of Alzheimer’s disease dementia: an analysis of US Medicare claims data

References

• Alzheimer’s Disease International. World Alzheimer report 2018: the state of the art of dementia research: new frontiers [Internet]. London: Alzheimer’s Disease International. Available from:https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf. Accessed. 2021 November5.
   Google Scholar
• Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17(3): 327–406.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3): 280–292.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4): 535–562.
   PubMed Web of Science ®Google Scholar
• Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3): 292–323.
   PubMed Web of Science ®Google Scholar
• Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452–1459.
   PubMed Web of Science ®Google Scholar
• Gerontological Society of America. The Gerontological Society of America Workgroup on Cognitive Impairment Detection and Earlier Diagnosis: report and recommendations [Internet]. Washington, DC: Gerontological Society of America 2021 . Available from: https://www.geron.org/images/gsa/documents/gsaciworkgroup2015report.pdf. Accessed. 2021 November 5.
   Google Scholar
• Dubois B, Padovani A, Scheltens P, et al. Timely diagnosis for Alzheimer’s disease: a literature review on benefits and challenges. J Alzheimers Dis.2016;49(3): 617–631.
   PubMed Web of Science ®Google Scholar
• Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med. 2006;145(10): 713–726.
   PubMed Web of Science ®Google Scholar
• Kishita N, Backhouse T, Mioshi E. Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with dementia: an overview of systematic reviews. J Geriatr Psychiatry Neurol. 2020;33(1):28–41.
   PubMed Web of Science ®Google Scholar
• Fukushima RLM, Do Carmo EG, Pedroso RDV, et al. Effects of cognitive stimulation on neuropsychiatric symptoms in elderly with Alzheimer’s disease: a systematic review. Dement Neuropsychol. 2016;10(3): 178–184.
   PubMedGoogle Scholar
• Liu JL, Hlavka JP, Hillestad R, et al. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer’s treatment [Internet]. Santa Monica (CA): RAND Corporation, 2017. Available from: https://www.rand.org/pubs/research_reports/RR2272.html. Accessed. 2021 November 5.
   Google Scholar
• Yuan J, Maserejian N, Liu Y, et al. Severity distribution of Alzheimer’s disease dementia and mild cognitive impairment in the Framingham Heart Study. J Alzheimers Dis. 2021;9(2): 807–817.
   Google Scholar
• Potashman M, Buessing M, Levitchi Benea M, et al. Estimating progression rates across the spectrum of Alzheimer’s disease for amyloid-positive individuals using National Alzheimer’s Coordinating Center data. Neurol Ther. 2021;10(2): 941–953. .
   PubMed Web of Science ®Google Scholar
• Crous-Bou M, Minguillon C, Gramunt N, et al. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther. 2017;9(1): 71.
   PubMed Web of Science ®Google Scholar
• Rakesh G, Szabo ST, Alexopoulos GS, et al. Strategies for dementia prevention: latest evidence and implications. Ther Adv Chronic Dis. 2017;8(8–9): 121–136.
   PubMed Web of Science ®Google Scholar
• Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10): 2029–2040.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Kesler SR, Noll KR, et al. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2): 123–138.
   PubMed Web of Science ®Google Scholar
• Galvin JE, Aisen P, Langbaum JB, et al. Early stages of Alzheimer’s disease: evolving the care team for optimal patient management. Front Neurol. 2021;11: 592302.
   PubMed Web of Science ®Google Scholar
• Tay L, Lim WS, Chan M, et al. New DSM-V neurocognitive disorders criteria and their impact on diagnostic classifications of mild cognitive impairment and dementia in a memory clinic setting. Am J Geriatr Psychiatry. 2015;23(8): 768–779.
   PubMed Web of Science ®Google Scholar
• Qato DM, Wilder J, and Schumm LP, et al. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States,2005 vs 2011. JAMA Intern Med.2016;176(4): 473–482.
   PubMed Web of Science ®Google Scholar
• Lee Q, Mocarski M, Sun SX. Benefits of early roflumilast treatment after hospital or emergency department discharge for a COPD exacerbation. Am Health Drug Benefits. 2016;9(3):140–150.
   PubMedGoogle Scholar
• Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6): 685–698.
   PubMedGoogle Scholar
• Saczynski J, Andrade S, Harrold L, et al. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: congestive heart failure [Internet]. White Oak (MD): US Food and Drug Administration, 2010. Available from: https://www.sentinelinitiative.org/sites/default/files/surveillance-tools/validations-literature/MS_HOI_CHFReport_0.pdf. Accessed 2021 Nov 5.
   Google Scholar
• Go AS, Singer D, Cheetham TC, et al. Mini-Sentinel medical product assessment: a protocol for assessment of dabigatran [Internet]. White Oak (MD): US Food and Drug Administration, 2015 . Available from: https://sentinelinitiative.org/sites/default/files/Drugs/Assessments/Mini-Sentinel_Protocol-for-Assessment-of-Dabigatran_0.pdf. 2021November 5.
   Google Scholar
• de Bruijn RF, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC Med. 2014;12(1):130.
   PubMedGoogle Scholar
• Burke SL, Cadet T, Alcide A, et al. Psychosocial risk factors and Alzheimer’s disease: the associative effect of depression, sleep disturbance, and anxiety. Aging Ment Health.2018;22(12): 1577–1584.
   PubMed Web of Science ®Google Scholar
• Cooper C, Sommerlad A, and Lyketsos CG, et al. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry.2015;172(4): 323–334.
   PubMed Web of Science ®Google Scholar
• Morley JE, Morris JC, Berg-Weger M, et al. Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. J Am Med Dir Assoc St Louis, MO, USA. 2015;16( 9):731–739.
   Google Scholar
• Wiesmann M, Kiliaan AJ, Claassen JAHR. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab. 2013;33(11):1696–1706.
   PubMed Web of Science ®Google Scholar
• Silva MVF, Loures CMG, Alves LCV, et al. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci.2019;26(1):33.
   PubMed Web of Science ®Google Scholar
• Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology.2011;76(17): 1485–1491.
   PubMed Web of Science ®Google Scholar
• Forrester SN, Gallo JJ, Smith GS, et al. Patterns of neuropsychiatric symptoms in mild cognitive impairment and risk of dementia. Am J Geriatr Psychiatry. 2016;24(2):117–125.
   PubMed Web of Science ®Google Scholar
• Geldmacher DS, Kirson NY, Birnbaum HG, et al. Pre-diagnosis excess acute care costs in Alzheimer’s patients among a US Medicaid population. Appl Health Econ Health Policy. 2013;11(4):407–413.
   PubMedGoogle Scholar
• Etgen T, Sander D, Bickel H, et al. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int. 2011;108(44):743–750.
   PubMed Web of Science ®Google Scholar
• Tatemichi TK, Desmond DW, Stern Y, et al. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry. 1994;57(2):202–207.
   PubMed Web of Science ®Google Scholar
• Loh KP, Janelsins MC, Mohile SG, et al. Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol. 2016;7(4):270–280.
   PubMed Web of Science ®Google Scholar
• 2019 American Geriatrics Society Beers Criteria® Update Expert Panel . American Geriatrics Society 2019 updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4): 674–694.
   PubMed Web of Science ®Google Scholar
• Cappetta K, Lago L, and Potter J, et al. Under-coding of dementia and other conditions indicates scope for improved patient management: a longitudinal retrospective study of dementia patients in Australia. Health Inf Manag. 2022;51(1): 32–44.
   PubMedGoogle Scholar
• Byhoff E, Harris JA, Ayanian JZ. Characteristics of decedents in Medicare Advantage and Traditional Medicare. JAMA Intern Med. 2016;176(7):1020–1023.
   PubMed Web of Science ®Google Scholar